SMMT * Stock Overview
A biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Summit Therapeutics Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$378.00 |
| 52 Week High | US$430.00 |
| 52 Week Low | US$258.50 |
| Beta | -0.97 |
| 11 Month Change | 46.23% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 46.23% |
Recent News & Updates
Recent updates
Shareholder Returns
| SMMT * | MX Biotechs | MX Market | |
|---|---|---|---|
| 7D | 46.2% | 0% | 0% |
| 1Y | n/a | 0% | 0% |
Return vs Industry: Insufficient data to determine how SMMT * performed against the MX Biotechs industry.
Return vs Market: Insufficient data to determine how SMMT * performed against the MX Market.
Price Volatility
| SMMT * volatility | |
|---|---|
| SMMT * Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 0% |
| Market Average Movement | 0% |
| 10% most volatile stocks in MX Market | 0% |
| 10% least volatile stocks in MX Market | 0% |
Stable Share Price: SMMT *'s share price has been volatile over the past 3 months compared to the MX market.
Volatility Over Time: Insufficient data to determine SMMT *'s volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 105 | Bob Duggan | www.summittxinc.com |
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company’s lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab.
Summit Therapeutics Inc. Fundamentals Summary
| SMMT * fundamental statistics | |
|---|---|
| Market cap | Mex$274.09b |
| Earnings (TTM) | -Mex$3.11b |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-88.0x
P/E RatioIs SMMT * overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SMMT * income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$161.69m |
| Earnings | -US$161.69m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.22 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 51.3% |
How did SMMT * perform over the long term?
See historical performance and comparison